Last reviewed · How we verify
Cefaclor Capsules
Cefaclor is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefaclor is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media.
At a glance
| Generic name | Cefaclor Capsules |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefaclor works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has a broader spectrum of activity than first-generation cephalosporins, particularly against gram-negative organisms and some anaerobes, while maintaining good gram-positive coverage.
Approved indications
- Bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Allergic reactions
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefaclor Capsules CI brief — competitive landscape report
- Cefaclor Capsules updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI